RxDoctor Payments Data

Lee Schwartzberg, MD

Medical Oncology · Reno, NVNPI 1306878228

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (50.7%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 53 manufacturers, the largest accounting for just 18.4%.

$810,520in general payments, 2019–2025

Across 647 payments — averaging $1252.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$149K
  • Daiichi Sankyo Inc.$143K
  • Cornerstone Specialty Network LLC$64K
  • Napo Pharmaceuticals Inc$63K
  • Seagen Inc.$44K
  • Merck$36K
  • plus $312K from 47 others
$5,926,801in research payments, 2019–2025

Across 404 payments — averaging $14,670 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$2.7M
  • Pfizer$1.5M
  • Merck$603K
  • Genentech, Inc.$526K
  • Puma Biotechnology, Inc.$80K
  • E.r. Squibb & Sons, L.L.C.$69K
  • plus $401K from 16 others
$50,000in ownership & investment interests, 2019–2025

Across 3 payments — averaging $16,667 each. An ownership or investment interest held by the physician or an immediate family member.

  • Cornerstone Specialty Network LLC$50K

What the payments were for

  • Consulting fees$411,32551%
  • Speaking & faculty fees$312,10339%
  • Travel & lodging$50,8076%
  • Food & beverage$15,0472%
  • Education$18,7402%
  • Other$2,4980%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few medical oncology providers in Nevadato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$36,529
Medicare patients
154
Services billed
383

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VitrakviLarotrectinib Sulfate29$882,576
IbrancePalbociclib11$193,152
Anastrozole233$6,804
Tamoxifen Citrate115$3,496
Letrozole71$1,615
Etodolac13$531
Oxybutynin Chloride ErOxybutynin Chloride20$438
Lidocaine-PrilocaineLidocaine/Prilocaine23$295
Prochlorperazine Maleate25$285
Dexamethasone33$260
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen12$149
Ondansetron Hcl31$122
Gabapentin11$83
Levothyroxine Sodium13$46

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerVitrakvi$18,489$882,57629 claims
PfizerIbrance$34,224$193,15211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few medical oncology providers in Nevadaon file to place this against a meaningful peer group, so we don't.

Other medical oncology in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →